MedTrace Logo

Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)

NCT07364331 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-26

No results posted yet for this study

Summary

This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.

Conditions

  • ADHD
  • Children
  • Adolescents

Interventions

DIETARY_SUPPLEMENT

Omega-3

EPA or DHA

DIETARY_SUPPLEMENT

Placebo

olive oil

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Pei-Chen Chang, PhD · China Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-04
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07364331 on ClinicalTrials.gov